Evidence map›Paper›PMID 36943605›Full record

ArticleMolecular biology reports2023

Harmaline exerts potentially anti-cancer effects on U-87 human malignant glioblastoma cells in vitro.

Mohammad Mahdi Vahedi, Ali Shahini, Mehran Mottahedi, Setareh Garousi, Seyed Ali Shariat Razavi, Ghazaleh Pouyamanesh, Amir R Afshari, Gordon A Ferns, Afsane Bahrami

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Effectiveness of harmaline along with meglumine antimoniate onVeterinary research forum : an international quarterly journal · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Anticancer and Antioxidant Activities of Methanolic Extract ofJournal of pharmacy & bioallied sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Nedaplatin/Pharmaceutics · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Mohammad Mahdi Vahedi *Department of Pharmacology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Ali Shahini *Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehran MottahediFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Setareh GarousiFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Ali Shariat RazaviNeurosurgery Department, Ghaem Hospital, Mashhad university of medical sciences, Mashhad, Iran.
Ghazaleh PouyamaneshDepartment of medical laboratory science, Mashhad branch, Islamic Azad University, Mashhad, Iran.
Amir R AfshariDepartment of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Gordon A FernsBrighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK.
Afsane BahramiClinical Research Development Unit, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. BahramiAF@mums.ac.ir.
Mashhad University of Medical Sciences · IRGhaem Hospital · IRBrighton and Sussex Medical School · GBIslamic Azad University, Mashhad · IRNorth Khorasan University of Medical Sciences · IRZahedan University of Medical Sciences · IR

Funding

Mashhad University of Medical Sciences Mashhad University of Medical Sciences
6 · The paper itself

Abstract

backgroundHarmaline is a β-carboline alkaloid that can be extracted from the seeds of Peganum harmala. Harmaline has been shown to exhibit a potent cytotoxic effect against tumor cells. In this study, the anti-glioblastoma activity of harmaline was investigated in vitro. METHODS AND

resultsCell viability, apoptosis, and cell cycle arrest were assessed in U-87 cells treated with harmaline at different doses. Reactive oxygen species (ROS) generation and the mRNA expression of apoptosis-associated genes were assessed. The anti-metastatic effect of harmaline on U-87 cells was evaluated by gelatin zymography assay where matrix metalloproteinase [MMP]-2/-9 enzymatic activity was measured, and the scratch assay was used to assess migratory responses. Flow cytometry demonstrated that harmaline could suppress the proliferation and induce sub-G1 cell cycle arrest and apoptotic cell death in glioblastoma cells. Harmaline treatment was also associated with an upregulation of the cell cycle-related genes, p21 and p53, and pro-apoptotic Bax, as well as the induction of ROS. The zymography assay indicated that the essential steps of metastasis were potently suppressed by harmaline through inhibiting the expression of MMP-2 and - 9. In addition, the migration of U-87 cells was significantly reduced after harmaline treatment.

conclusionOur data suggest a basis for further research of harmaline which has potential cytotoxic activities in glioblastoma cells; inducing cell cycle arrest and apoptosis, repression of migration, possibly invasion, and metastasis.

Indexed as

Antineoplastic AgentsGlioblastomaApoptosisCell Line, TumorCell ProliferationHarmalineHumansReactive Oxygen SpeciesAntineoplastic AgentsHarmalineReactive Oxygen SpeciesApoptosisCell cycle arrestHarmalineInvasionMigration

Identifiers

PMID36943605
OpenAlexW4328049831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.